N-乙基-3-硝基-2-吡啶胺 | 26820-65-5

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: N-乙基-3-硝基-2-吡啶胺
• 英文名称: ethyl-(3-nitropyridin-2-yl)amine
• 英文别名: N-ethyl-3-nitropyridine-2-amine；2-(ethylamino)-3-nitropyridine；N-ethyl-3-nitropyridin-2-amine；2-ethylamino-3-nitropyridine
• CAS: 26820-65-5
• 化学式: C₇H₉N₃O₂
• mdl: MFCD08692122
• 分子量: 167.167
• InChiKey: DDBQQNCEHLMYGB-UHFFFAOYSA-N

物化性质

• 沸点：
  298.6±25.0 °C(Predicted)
• 密度：
  1.281±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Ethylamino-3-nitropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Ethylamino-3-nitropyridine
CAS number: 26820-65-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H9N3O2
Molecular weight: 167.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-乙基-3-硝基-2-吡啶胺 在 盐酸 、 硫酸 、 sodium hydride 、 溶剂黄146 、 N,N-二异丙基乙胺 、 sodium iodide 、 tin(ll) chloride 、 sodium nitrite 作用下， 以 四氢呋喃 、 xylene 为溶剂， 反应 9.33h， 生成 5,11-dihydro-11-ethyl-8-iodo-5-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
  参考文献：
  名称：

  Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 7. 8-Arylethyldipyridodiazepinones as Potent Broad-Spectrum Inhibitors of Wild-Type and Mutant Enzymes

  摘要：

  Like other nonnucleoside inhibitors of HIV-1 reverse transcriptase, the dipyridodiazepinone nevirapine (Viramune, 1) selects for drug resistant variants of HIV-1, both in cell culture and in patients. In particular, the mutation of residue 181 from tyrosine to cysteine (Y181C) is associated with resistance to most reported nonnucleoside inhibitors. Introduction of an arylethyl substituent at the 8-position of the tricyclic dipyridodiazepinone skeleton confers enhanced potency against Y181C RT. Several analogues of this series display good broad spectrum potency against a panel of mutant enzymes.

  DOI：

  10.1021/jm9707028
• 作为产物：
  描述：

  2-氯-3-硝基吡啶 在 乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 N-乙基-3-硝基-2-吡啶胺
  参考文献：
  名称：

  [EN] NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
  [FR] INHIBITEURS NON NUCLEOSIDIQUES DE LA TRANSCRIPTASE INVERSE

  摘要：

  由以下公式表示的化合物，其中R1为H、卤素、(C1-4)烷基、O(C1-4)烷基和卤代烷基；R2为H或甲基；R3为H或(C1-4)烷基；R4为H或(C1-4)烷基；R5为(C1-4)烷基、(C1-4)烷基(C3-7)环烷基或(C3-7)环烷基；W为具有从N或S中选择的一个或两个杂原子的融合苯基5或6成员杂环；或W为苯基、1,1'-联苯、2,3-二氢-1H-茚烯、1,2,3,4-四氢萘基或萘基；所述的W可以选择地被(C1-4)烷基取代，而该烷基可以选择地被羧基或(C1-4)烷氧羰基取代，或其盐或酯。这些化合物对HIV的野生型、单突变株和双突变株具有抑制活性。

  公开号：

  WO2004026875A1

文献信息

• 8-arylalkyl- and
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US05705499A1

  公开（公告）日：1998-01-06

  Disclosed are novel 8-arylalkyl-5,11-dihydro-6H-dipyrido\x9b3,2-b:2',3'-e!\x9b1,4!diazepines. These are useful in the treatment of HIV-1 infection.

  公开的是新型的8-芳基烷基-5,11-二氢-6H-二吡啶[3,2-b:2',3'-e]![1,4]二氮杂环。这些化合物在治疗HIV-1感染中是有用的。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20040106791A1

  公开（公告）日：2004-06-03

  Compounds represented by formula I: 1 wherein R 1 is H, halogen, (C 1-4 )alkyl, O(C 1-4 )alkyl, and haloalkyl; R 2 is H or (C 1-4 )alkyl; R 3 is H or (C 1-4 )alkyl; R 4 is (C 1-4 )alkyl, (C 1-4 )alkyl(C 3-7 )cycloalkyl, or (C 3-7 )cycloalkyl; and Q is a fused phenyl-5 or 6-membered saturated heterocycle having one to two heteroatoms selected from O and N, said Q being optionally substituted with hydroxy, or (C 1-4 )alkyl which in turn maybe optionally substituted with pyridinyl-N-oxide or C(O)OR wherein R is H or (C 1-4 )alkyl; or a salt thereof. The compounds have inhibitory activity against Wild Type, and single and double mutants strains, of HIV.

  化合物的化学式表示为I： 其中R1为H、卤素、(C1-4)烷基、O(C1-4)烷基和卤代烷基；R2为H或(C1-4)烷基；R3为H或(C1-4)烷基；R4为(C1-4)烷基、(C1-4)烷基(C3-7)环烷基或(C3-7)环烷基；Q为融合的带有一个到两个来自O和N的杂原子的饱和的含有5个或6个成员的苯基杂环，所述Q可以选择地用羟基或(C1-4)烷基取代，而(C1-4)烷基可以选择地用吡啶-N-氧化物或C(O)OR取代，其中R为H或(C1-4)烷基；或其盐。这些化合物对HIV的野生型、单突变体和双突变体菌株具有抑制活性。
• PYRIDYL CARBENE PHOSPHORESCENT EMITTERS
  申请人：Wu Yonggang

  公开号：US20120228583A1

  公开（公告）日：2012-09-13

  Organometallic compounds comprising an imidazole carbene ligand having a N-containing ring fused to the imidazole ring are provided. In particular, the N-containing ring fused to the imidazole ring may contain one nitrogen atom or more than one nitrogen atom. These compounds may demonstrate high photoluminescent (PL) efficiency, Gaussian emission spectra, and/or short excited state lifetimes. These materials may be especially useful as blue phosphorescent emitters.

  提供了包含咪唑卡宾配体的有机金属化合物，其中该配体具有与咪唑环融合的含氮环。具体来说，与咪唑环融合的含氮环可能包含一个或多个氮原子。这些化合物可能表现出高光致发光（PL）效率、高斯发射光谱和/或短激发态寿命。这些材料可能特别适用作为蓝色磷光发射体。
• 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US05366972A1

  公开（公告）日：1994-11-22

  Disclosed are novel 5,11-dihydro-6H-dipyrido[3,2-b; 2',3'-e][1,4]diazepines. These are useful in the prevention or treatment of HIV infection.

  本文披露了新型的5,11-二氢-6H-二吡啶并[3,2-b; 2',3'-e][1,4]二氮杂环。这些化合物在预防或治疗HIV感染方面具有用处。
• [EN] NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS<br/>[FR] INHIBITEURS NON NUCLEOSIDIQUES DE TRANSCRIPTASE INVERSE
  申请人：BOEHRINGER INGELHEIM CA LTD

  公开号：WO2001096338A1

  公开（公告）日：2001-12-20

  Provided are compounds of general formula (I), wherein R2 is selected from the group consisting of H, F, Cl, (C¿1-4?) alkyl, (C3-4) cycloalkyl and CF3; R?4¿ is H or Me; R5 is H, Me or Et, with the proviso that R?4 and R5¿ are not both Me, and if R4 is Me then R5 cannot be Et; R11 is Et, cyclopropyl, propyl, isopropyl, or isobutyl; and Q is selected from the group consisting of (II), (III), (IV) and (V); and pharmaceutically acceptable salts thereof, as inhibitors of HIV reverse transcriptase, wild-type and several mutant strains.

  提供了一般式为(I)的化合物，其中R2从H、F、Cl、(C1-4)烷基、(C3-4)环烷基和CF3中选择；R4为H或Me；R5为H、Me或Et，但R4和R5不能同时为Me，如果R4为Me，则R5不能为Et；R11为Et、环丙基、丙基、异丙基或异丁基；Q从(II)、(III)、(IV)和(V)中选择；以及其药学上可接受的盐，作为HIV逆转录酶、野生型和几种突变株的抑制剂。